<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="xlhi" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">xlhi</book-part-id>
      <title-group>
        <title>X-Linked Hyper IgM Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonyms: HIGM1, Hyper-IgM Syndrome 1, X-Linked Hyper-IgM Immunodeficiency, XHIM</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Johnson</surname>
            <given-names>Judith</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Project Manager, Divison of Human Genetics <break/>Cincinnati Children's Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>juditha.johnson@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Filipovich</surname>
            <given-names>Alexandra H</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Professor, Division of Bone Marrow Transplant and Immune Deficiency<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>lisa.filipovich@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Kejian</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <aff>Associate Professor of Pediatrics<break/>Director, Molecular Genetics Laboratory<break/>Division of Human Genetics<break/>Cincinnati Children's Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>kejian.zhang@cchmc.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>31</day>
          <month>5</month>
          <year>2007</year>
        </date>
        <date date-type="updated">
          <day>21</day>
          <month>6</month>
          <year>2012</year>
        </date>
        <date date-type="revised">
          <day>24</day>
          <month>1</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="xdp" document-type="chapter">X-Linked Dystonia-Parkinsonism</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="rickets-xlh" document-type="chapter">X-Linked Hypophosphatemia</related-object>
      <abstract id="xlhi.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>X-linked hyper IgM syndrome (HIGM1), a disorder of abnormal T- and B-cell function, is characterized by low serum concentrations of IgG and IgA and normal or elevated serum concentrations of IgM. Mitogen proliferation may be normal, but NK- and T-cell cytotoxicity are frequently impaired. Antigen-specific responses may be decreased or absent. The range of clinical findings varies, even within the same family. More than 50% of males with HIGM1 develop symptoms by age one year, and more than 90% are symptomatic by age four years. HIGM1 usually presents in infancy with recurrent upper- and lower-respiratory tract bacterial infections, opportunistic infections, and recurrent or protracted diarrhea associated with failure to thrive. Neutropenia, thrombocytopenia, and anemia are common. Autoimmune and/or inflammatory disorders, such as sclerosing cholangitis, have been reported. Significant neurologic complications, often the result of a CNS infection, are seen in 10%-15% of affected males. Liver disease, including primary cirrhosis and carcinomas (bile duct carcinomas, hepatocellular carcinomas, adenocarcinomas of the liver and gall bladder), and tumors of the gastrointestinal tract (carcinoid of the pancreas, glucagonoma of the pancreas) are common life-threatening complications in adolescents and young adults with HIGM1. Affected males are also at an increased risk for lymphoma, particularly Hodgkin's disease associated with Epstein-Barr virus infection.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of HIGM1 is based on a combination of clinical findings, family history, absent or decreased expression of the CD40 ligand (CD40L) protein on flow cytometry following in vitro stimulation of white cells, and molecular genetic testing of <italic toggle="yes">CD40LG</italic> (previously known as <italic toggle="yes">TNFSF5</italic> or <italic toggle="yes">CD154</italic>), the only gene in which mutation is known to cause HIGM1. Direct sequencing of the entire coding region and intron/exon boundaries detects pathogenic variants in approximately 95% of affected males.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Allogeneic hematopoietic cell transplantation (HCT) (the only curative treatment currently available), ideally performed prior to onset of life-threatening complications and organ damage; recombinant granulocyte colony-stimulating factor (G-CSF) for chronic neutropenia; appropriate antimicrobial therapy for infections; immunosuppressants for autoimmune disorders.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Prophylaxis for pneumonia secondary to <italic toggle="yes">Pneumocystis jiroveci</italic>; intravenous immune globulin (IVIG) by age six months to prevent overwhelming infection from encapsulated bacteria.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Drink only purified water in areas where cryptosporidium may be in the water supply.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual pulmonary function tests after age seven years; annual endoscopic evaluation.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Evaluate newborn at-risk male relatives with assay of CD40L protein expression by flow cytometry and <italic toggle="yes">CD40LG</italic> molecular genetic testing if the pathogenic variant in the family is known, so that morbidity and mortality can be reduced by early diagnosis and treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>X-linked hyper IgM syndrome (HIGM1) is inherited in an X-linked manner. Female carriers are asymptomatic and have no immunologic or biochemical markers of the disorder. Female carriers have a 50% chance of transmitting the pathogenic variant in each pregnancy; males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers. Affected males pass the pathogenic variant to all their daughters and none of their sons. Carrier testing of at-risk female relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant has been identified in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="xlhi.Diagnosis">
        <title>Diagnosis</title>
        <sec id="xlhi.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>The diagnosis of X-linked hyper IgM syndrome (HIGM1) should be considered in males with serum IgG concentration two or more SD below normal for age and any one or more of the following diagnostic criteria from the recommendations of the European Society for Immunodeficiencies [<xref ref-type="bibr" rid="xlhi.REF10">ESID Working Party 2006</xref>]:</p>
          <p><bold>Definite diagnosis</bold> (decreased serum IgG and one of the following):</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathogenic variant in <italic toggle="yes">CD40LG</italic></p>
            </list-item>
            <list-item>
              <p>Family history of one or more maternally related males with an HIGM1 phenotype or diagnosis</p>
            </list-item>
          </list>
          <p><bold>Probable diagnosis</bold> (decreased serum IgG and all of the following):</p>
          <list list-type="bullet">
            <list-item>
              <p>Normal number of T cells and normal T cell proliferation to mitogens</p>
            </list-item>
            <list-item>
              <p>Normal or elevated numbers of B cells but no antigen-specific IgG antibody</p>
            </list-item>
            <list-item>
              <p>One or more of the following infections or complications:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Recurrent bacterial infections in the first five years of life</p>
                </list-item>
                <list-item>
                  <p><italic toggle="yes">Pneumocystis carinii</italic> infection in the first year of life</p>
                </list-item>
                <list-item>
                  <p>Neutropenia</p>
                </list-item>
                <list-item>
                  <p>Cryptosporidium-related diarrhea</p>
                </list-item>
                <list-item>
                  <p>Sclerosing cholangitis</p>
                </list-item>
                <list-item>
                  <p>Parvovirus induced aplastic anemia</p>
                </list-item>
                <list-item>
                  <p>Absent CD40 ligand expression</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Possible diagnosis</bold> (decreased serum IgG, normal numbers of T and B cells and one or more of the following):</p>
          <list list-type="bullet">
            <list-item>
              <p>Serum IgM concentration two or more SD above normal for age</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">Pneumocystis carinii</italic> infection in the first year of life</p>
            </list-item>
            <list-item>
              <p>Parvovirus induced aplastic anemia</p>
            </list-item>
            <list-item>
              <p>Cryptosporidium-related diarrhea</p>
            </list-item>
            <list-item>
              <p>Severe liver disease (typically sclerosing cholangitis)</p>
            </list-item>
          </list>
        </sec>
        <sec id="xlhi.Testing">
          <title>Testing</title>
          <p>Although no uniform abnormalities are observed on routine immunologic laboratory testing of males with HIGM1, the following test results suggest the diagnosis of HIGM1:</p>
          <list list-type="bullet">
            <list-item>
              <p>Normal or elevated serum concentrations of IgM&#x000a0;<sup>1</sup> and IgD&#x000a0;<sup>2</sup></p>
            </list-item>
            <list-item>
              <p>Absent or very low serum concentrations of IgG&#x000a0;<sup>2</sup> and IgA&#x000a0;<sup>2</sup></p>
            </list-item>
            <list-item>
              <p>Absent IgG specific antibodies</p>
            </list-item>
            <list-item>
              <p>Normal or increased number of B cells&#x000a0;<sup>2</sup></p>
            </list-item>
            <list-item>
              <p>Normal number and distribution of CD4+ and CD8 + T-cell subsets&#x000a0;<sup>3</sup></p>
            </list-item>
            <list-item>
              <p>Normal T-cell proliferation in response to mitogens&#x000a0;<sup>3</sup></p>
            </list-item>
          </list>
          <p>Notes:</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>A minority of males with HIGM1 have decreased IgM concentrations.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Serum concentrations of IgM, IgD, IgG, IgA, and B-cell markers are not reliable in a neonate.</p>
            </list-item>
            <list-item>
              <label>3</label>
              <p>Enumeration of lymphocyte subsets, mitogen responses, and other tests of cell-mediated immunity can vary from person to person and over time in a specific person.</p>
            </list-item>
          </list>
          <p><bold>Measurement by flow cytometry of CD40 ligand (CD40L) protein expression after in vitro stimulation of T cells.</bold> In the resting state, only a low level of CD40L protein expression is seen on normal CD4+ T cells. After in vitro stimulation:</p>
          <list list-type="bullet">
            <list-item>
              <p>Controls show increased expression (up-regulation) of CD40L protein in the majority of CD4+ T cells.</p>
              <p>Note: Infants under age six months may not express normal amounts of CD40L protein [<xref ref-type="bibr" rid="xlhi.REF.gilmour.2003.256">Gilmour et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>Persons with HIGM1 do not show increased expression of CD40L protein in CD4+ T cells.</p>
            </list-item>
          </list>
          <sec id="xlhi.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">CD40LG</italic> (previously known as <italic toggle="yes">TNFSF5</italic> or <italic toggle="yes">CD154</italic>) is the only gene in which mutation is known to cause X-linked hyper IgM syndrome (HIGM1).</p>
            <table-wrap id="xlhi.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in X-Linked Hyper IgM Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_2">Test Method</th>
                    <th id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_3">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                    <th headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4" id="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Females</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">CD40LG</italic>
                    </td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">95%&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">95%&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or whole-gene deletion</td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">5%</td>
                    <td headers="hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_1_4 hd_h_xlhi.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">5%&#x000a0;<sup>8</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="xlhi.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="xlhi" object-id="xlhi.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="xlhi.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="xlhi.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="xlhi.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
                </fn>
                <fn id="xlhi.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of unknown significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="xlhi.TF.1.5">
                  <label>5. </label>
                  <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative exon, multiexon, or whole-gene deletion on the X chromosome in affected males; confirmation may require additional testing by deletion/duplication analysis.</p>
                </fn>
                <fn id="xlhi.TF.1.6">
                  <label>6. </label>
                  <p>Sequence analysis of genomic DNA cannot detect deletion of one or more exons or the entire X-linked gene in a heterozygous female.</p>
                </fn>
                <fn id="xlhi.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="xlhi.TF.1.8">
                  <label>8. </label>
                  <p>Although it is technically feasible for this method to detect a deletion in a carrier female whether or not the deletion has previously been identified in the family, some laboratories may offer deletion testing only to those at-risk women whose family-specific deletion is known.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="xlhi.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband</bold> with the following findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Absent or very low serum concentrations of IgG and IgA</p>
              <p>Note: These findings are not universal.</p>
            </list-item>
            <list-item>
              <p>Normal or elevated serum concentrations of IgM and IgD</p>
            </list-item>
            <list-item>
              <p>Normal:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Number and distribution of CD4+ and CD8+ T-cell subsets</p>
                </list-item>
                <list-item>
                  <p>T-cell proliferation in response to mitogens</p>
                </list-item>
                <list-item>
                  <p>Number of B cells</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Perform the following tests:</p>
          <list list-type="bullet">
            <list-item>
              <p>Assay for absent or decreased CD40L protein expression</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing of <italic toggle="yes">CD40LG</italic>, first using sequence analysis. If lack of amplification suggests a deletion, it must be confirmed by deletion/duplication analysis.</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variant in the family.</p>
          <p>Note: (1) Carriers are heterozygotes for this X-linked disorder and typically do not develop clinical findings related to the disorder. (2) Identification of female carriers requires either (a) prior identification of the pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and then, if no pathogenic variant is identified, by methods to detect gross structural abnormalities.</p>
          <p><bold>Predictive testing for at-risk asymptomatic males</bold> is facilitated by prior identification of the pathogenic variant in the family.</p>
          <p>If a pathogenic variant has not been previously documented in the family, full sequence analysis of <italic toggle="yes">CD40LG</italic> in the at-risk newborn will detect a pathogenic variant. If lack of amplification suggests a deletion, it must be confirmed by deletion/duplication analysis.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="xlhi.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="xlhi.Clinical_Description">
          <title>Clinical Description</title>
          <p>X-linked hyper IgM syndrome (HIGM1), a disorder of abnormal T- and B-cell function, is characterized by low serum concentrations of IgG and IgA and normal or elevated serum concentrations of IgM. Mitogen proliferation may be normal but NK- and T-cell cytotoxicity is frequently impaired. Antigen-specific responses may be decreased or absent. The range of clinical findings varies, even within the same family. More than 50% of males with HIGM1 develop symptoms by age one year, and more than 90% are symptomatic by age four years [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>].</p>
          <p>HIGM1 usually presents in infancy with recurrent upper- and lower-respiratory tract bacterial infections, opportunistic infections, and recurrent or protracted diarrhea. Hematologic disorders including neutropenia, thrombocytopenia, and anemia are common [<xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>].</p>
          <p>Autoimmune and/or inflammatory disorders (e.g., sclerosing cholangitis) have been reported [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.jesus.2008.s62">Jesus et al 2008</xref>, <xref ref-type="bibr" rid="xlhi.REF.bussone.2009.332">Bussone &#x00026; Mouthon 2009</xref>]. Liver disease (including primary cirrhosis and carcinomas) in addition to tumors of the gastrointestinal tract are common life-threatening medical complications in adolescents and young adults with HIGM1.</p>
          <p><bold>Infection.</bold> Increased susceptibility to recurrent bacterial infections results in pneumonia, frequent sinopulmonary infections, and recurrent otitis media in infancy and childhood. Invasive fungal infections (primarily <italic toggle="yes">Candida</italic>, <italic toggle="yes">Cryptococcus</italic>, and <italic toggle="yes">Histoplasma</italic>) present a significant risk in affected individuals [<xref ref-type="bibr" rid="xlhi.REF.antachopoulos.2010.1335">Antachopoulos 2010</xref>]. Boys with HIGM1 are also at a significant risk for opportunistic infections from <italic toggle="yes">Pneumocystis jeroveci</italic> (formerly known as <italic toggle="yes">Pneumocystis carinii</italic> (PCP) and <italic toggle="yes">Cryptosporidium parvum</italic>. <italic toggle="yes">Pneumocystis jeroveci</italic> pneumonia is the first clinical symptom of HIGM1 in more than 40% of infants with the disorder [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>] and accounts for 10%-15% of the mortality associated with HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>].</p>
          <p><bold>Chronic diarrhea and malnutrition.</bold> Chronic diarrhea is a frequent complication of HIGM1, occurring in approximately one third of affected males [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>]. Recurrent or protracted diarrhea may result from infection with <italic toggle="yes">Cryptosporidium parvum</italic> or other microorganisms; however, in at least 50% of males with recurrent or protracted diarrhea, no infectious agent can be detected [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>]. Failure to thrive is a serious complication of chronic diarrhea.</p>
          <p><bold>Hematologic abnormalities.</bold> Neutropenia, and, less frequently, anemia or thrombocytopenia, occurs in a majority of males with HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>].</p>
          <p><bold>Neurologic involvement.</bold> Significant neurologic complications, often the result of a CNS infection, are seen in 10%-15% of males with HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>]. However, in at least one half of affected individuals a specific infectious agent cannot be isolated [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>].</p>
          <p><bold>Liver disease and liver/gastrointestinal carcinoma.</bold> Liver disease, a serious complication of HIGM1, historically was observed in more than 80% of affected males by age 20 years [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>]. Hepatitis and sclerosing cholangitis are frequent and may or may not result from an identifiable infectious agent.</p>
          <p>Malignancies of the liver and gastrointestinal tract including bile duct carcinomas [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.filipovich.2004">Filipovich &#x00026; Gross 2004</xref>], hepatocellular carcinomas [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>], carcinoid of the pancreas [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>], glucagonoma of the pancreas [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>], and adenocarcinomas of the liver and gall bladder [<xref ref-type="bibr" rid="xlhi.REF.hayward.1997.977">Hayward et al 1997</xref>] are common complications of HIGM1 in adolescents and young adults and account for approximately 25% of the mortality associated with HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>]. Less commonly, neuroendocrine carcinomas are also seen [<xref ref-type="bibr" rid="xlhi.REF.erdos.2008.455">Erdos et al 2008</xref>].</p>
          <p><bold>Lymphoma.</bold> Males with HIGM1 have an increased risk for lymphoma, particularly Hodgkin's disease associated with Epstein-Barr virus infection [<xref ref-type="bibr" rid="xlhi.REF.filipovich.2004">Filipovich &#x00026; Gross 2004</xref>].</p>
          <p><bold>Other</bold> reported complications of HIGM1 include, rarely, autoimmune retinopathy [<xref ref-type="bibr" rid="xlhi.REF.schuster.2005.235">Schuster et al 2005</xref>] and cutaneous granulomas [<xref ref-type="bibr" rid="xlhi.REF.gallerani.2004.39">Gallerani et al 2004</xref>].</p>
          <p><bold>Life span.</bold> The reported median survival of males with HIGM1 who do not undergo successful allogeneic bone marrow transplantation is less than 25 years [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>]. <italic toggle="yes">Pneumocystis jeroveci</italic> pneumonia in infancy, liver disease, and carcinomas of the liver and gastrointestinal tract in adolescence or young adulthood are the major causes of death [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>, <xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>].</p>
        </sec>
        <sec id="xlhi.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Males with HIGM1 show remarkable variability in clinical symptoms.</p>
          <p>In general, no good correlation between genotype and phenotype has been observed in HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.notarangelo.2000.399">Notarangelo &#x00026; Hayward 2000</xref>, <xref ref-type="bibr" rid="xlhi.REF.prasad.2005.90">Prasad et al 2005</xref>].</p>
          <p>The <xref ref-type="table" rid="xlhi.T.selected_cd40lg_pathogenic_varian">p.Thr254Met</xref> pathogenic variant has been reported in three unrelated families with mild disease [<xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>]. Whether or not this is a true association needs to be evaluated with study of additional families with the pathogenic variant.</p>
        </sec>
        <sec id="xlhi.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is complete in males with a <italic toggle="yes">CD40LG</italic> pathogenic variant.</p>
        </sec>
        <sec id="xlhi.Anticipation">
          <title>Anticipation</title>
          <p>Anticipation has not been documented in HIGM1.</p>
        </sec>
        <sec id="xlhi.Prevalence">
          <title>Prevalence</title>
          <p>The estimated prevalence of HIGM1 is 2:1,000,000 males [<xref ref-type="bibr" rid="xlhi.REF.winkelstein.2003.373">Winkelstein et al 2003</xref>].</p>
          <p>HIGM1 has been reported in families of European, African, and Asian descent; thus, no evidence exists for a racial or ethnic predilection.</p>
        </sec>
      </sec>
      <sec id="xlhi.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>HIGM1 is the only disorder known to be associated with mutation of <italic toggle="yes">CD40LG</italic>.</p>
      </sec>
      <sec id="xlhi.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS308230">Immunodeficiency with Hyper-IgM: OMIM Phenotypic Series</ext-link>, a table of similar phenotypes that are genetically diverse.</p>
        <p>The differential diagnosis of X-linked hyper IgM syndrome (HIGM1) includes the following disorders.</p>
        <p>
          <bold>Non X-linked forms of HIGM</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p>
              <bold>HIGM2</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Pathogenic variants in the activation-induced cytidine deaminase gene (<italic toggle="yes">AICDA</italic>) result in HIGM2, characterized by abnormalities in B-cell differentiation resulting in recurrent bacterial, respiratory, and gastrointestinal infections, but rarely opportunistic infections. Lymphoid hyperplasia is common [<xref ref-type="bibr" rid="xlhi.REF.minegishi.2000.203">Minegishi et al 2000</xref>, <xref ref-type="bibr" rid="xlhi.REF.revy.2000.565">Revy et al 2000</xref>, <xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>]. Inheritance is autosomal recessive.</p>
              </list-item>
              <list-item>
                <p>An autosomal dominant form of hyper IgM syndrome has been reported in four unrelated families with an identical pathogenic nonsense variant (p.Arg190Ter) in <italic toggle="yes">AICDA</italic> (reference sequence <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_020661.2">NM_020661.2</ext-link>) [<xref ref-type="bibr" rid="xlhi.REF.durandy.2005.67">Durandy et al 2005</xref>].</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold>HIGM3.</bold> Biallelic pathogenic variants in <italic toggle="yes">CD40</italic>, the receptor of CD40LG, are causative. HIGM3 is clinically indistinguishable from HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.ferrari.2001.12614">Ferrari et al 2001</xref>]. Inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p><bold>HIGM4.</bold> Fifteen individuals with an unidentified form of HIGM with decreased production of IgG and a somewhat milder clinical course than HIGM2 have been reported [<xref ref-type="bibr" rid="xlhi.REF.imai.2003.136">Imai et al 2003</xref>]. The genetic defect(s) underlying HIGM4 has not been determined.</p>
          </list-item>
          <list-item>
            <p><bold>HIGM5.</bold> Biallelic pathogenic variants in <italic toggle="yes">UNG</italic> are causative. HIGM5 resembles HIGM2. Inheritance is autosomal recessive [<xref ref-type="bibr" rid="xlhi.REF.imai.2003.136">Imai et al 2003</xref>].</p>
          </list-item>
        </list>
        <p><bold>Common variable immunodeficiency (CVID),</bold> particularly hypogammaglobulinemia identified in the first decade of life. As in HIGM1, CD40LG protein may be reduced in individuals with CVID. In contrast to HIGM1, CVID may be associated with a decreased number of total T cells or decreased T-cell function. The genetic etiology of most cases of CVID is currently unknown. See <xref ref-type="bibr" rid="xlhi.REF.goldacker.2005.504">Goldacker &#x00026; Warnatz [2005]</xref>, <xref ref-type="bibr" rid="xlhi.REF.salzer.2006.377">Salzer &#x00026; Grimbacher [2006]</xref>, <xref ref-type="bibr" rid="xlhi.REF.park.2011.41">Park et al [2011]</xref>, and <xref ref-type="bibr" rid="xlhi.REF.yong.2011.47">Yong et al [2011]</xref> for current reviews of CVID.</p>
        <p><bold>Severe combined immunodeficiency.</bold> Any one of the severe combined immunodeficiencies (SCIDs) must be considered in infants presenting with <italic toggle="yes">Pneumocystis jeroveci</italic> pneumonia. SCID usually presents with absent T-cell function, quantitative abnormalities of T lymphocyte populations, and markedly decreased mitogen function irrespective of SCID genotype. <related-object link-type="booklink" source-id="gene" document-id="x-scid" document-type="chapter">X-linked SCID</related-object> is caused by pathogenic variants in <italic toggle="yes">IL2RG</italic>. Biallelic pathogenic variants in multiple other genes result in autosomal recessive forms of SCID. See <xref ref-type="bibr" rid="xlhi.REF.sponzilli.2011.5">Sponzilli &#x00026; Notarangelo [2011]</xref> and <xref ref-type="bibr" rid="xlhi.REF.aloj.2012.43">Aloj et al [2012]</xref>.</p>
        <p><bold>Agammaglobulinemia.</bold> Any one of the disorders associated with agammaglobulinemia should be considered as part of the differential diagnosis of HIGM1. <related-object link-type="booklink" source-id="gene" document-id="xla" document-type="chapter">X-linked agammaglobulinemia</related-object> (XLA) typically presents in the first year of life with recurrent bacterial infections. Opportunistic viral infections such as <italic toggle="yes">Pneumocystis jeroveci</italic> pneumonia are rare, as are hematologic disorders such as neutropenia. In contrast to HIGM1, XLA typically presents with absence of CD19+ B cells. XLA is caused by pathogenic variants in <italic toggle="yes">BTK</italic>. Pathogenic variants in several other genes result in autosomal dominant and autosomal recessive forms of agammaglobulinemia. See <xref ref-type="bibr" rid="xlhi.REF.bonilla.2006.s435">Bonilla &#x00026; Geha [2006]</xref> for a current review of these disorders.</p>
        <p><bold>HIV infection.</bold> Infection with HIV should be considered in any infant presenting with <italic toggle="yes">Pneumocystis jeroveci</italic> pneumonia.</p>
        <p><bold>Transient hypogammaglobulinemia of infancy.</bold> Transient hypogammaglobulinemia of infancy is characterized by normal antibody production, normal growth patterns, and lack of opportunistic infections.</p>
        <p><bold><italic toggle="yes">IKBKG</italic>.</bold> Pathogenic variants in <italic toggle="yes">IKBKG</italic> (formerly known as <italic toggle="yes">NEMO</italic>) may result in a hyper IgM syndrome, generally associated with <related-object link-type="booklink" source-id="gene" document-id="x-hed" document-type="chapter">hypohydrotic ectodermal dysplasia</related-object> [<xref ref-type="bibr" rid="xlhi.REF.jain.2001.223">Jain et al 2001</xref>]. Serious infections, including opportunistic infections, are a common complication at any age. Inheritance is X-linked.</p>
      </sec>
      <sec id="xlhi.Management">
        <title>Management</title>
        <sec id="xlhi.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>Following the diagnosis of X-linked hyper IgM syndrome (HIGM1), the GI and respiratory tracts should be evaluated for overt or occult infections.</p>
        </sec>
        <sec id="xlhi.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The only curative treatment currently available for HIGM1 is allogeneic hematopoietic cell transplantation (HCT), ideally prior to onset of a life-threatening complication and organ damage [<xref ref-type="bibr" rid="xlhi.REF.levy.1997.47">Levy et al 1997</xref>]. Currently, boys with HIGM1 who receive allogeneic HCT have a 70%-75% long-term survival rate [<xref ref-type="bibr" rid="xlhi.REF.tomizawa.2004.33">Tomizawa et al 2004</xref>, <xref ref-type="bibr" rid="xlhi.REF.tsuji.2006.469">Tsuji et al 2006</xref>]. Modified conditioning regimens prior to HCT may be necessary in individuals with preexisting liver disease [<xref ref-type="bibr" rid="xlhi.REF.dogu.2011.349">Dogu et al 2011</xref>].</p>
          <p>For a concise summary of current clinical management practices in this disorder, see <xref ref-type="bibr" rid="xlhi.REF.davies.2010.167">Davies &#x00026; Thrasher [2010]</xref>.</p>
          <p>
            <bold>Other</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Total parenteral nutrition may be required.</p>
            </list-item>
            <list-item>
              <p>Treat chronic neutropenia with recombinant granulocyte colony-stimulating factor (G-CSF).</p>
            </list-item>
            <list-item>
              <p>Institute appropriate antimicrobial therapy for infections.</p>
            </list-item>
            <list-item>
              <p>Aggressively evaluate pulmonary infections, including the use of diagnostic bronchoalveolar lavage, to define the specific etiology.</p>
            </list-item>
            <list-item>
              <p>Some males with end-stage sclerosing cholangitis have been treated successfully with orthotropic liver transplantation closely associated with allogeneic bone marrow transplantation.</p>
            </list-item>
            <list-item>
              <p>Treat lymphomas and GI cancer.</p>
            </list-item>
            <list-item>
              <p>Treatment of autoimmune disorders usually involves judicious use of immunosuppressants tailored to the individual's diagnosis.</p>
            </list-item>
            <list-item>
              <p>Liver disease, including primary cirrhosis and carcinomas, in addition to tumors of the gastrointestinal tract, complicate the management of older individuals with HIGM1 [<xref ref-type="bibr" rid="xlhi.REF.lee.2005.1881">Lee et al 2005</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="xlhi.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>The following methods are used to prevent infection:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Antibiotic prophylaxis.</bold> Prophylaxis for pneumonia secondary to <italic toggle="yes">Pneumocystis jiroveci</italic> (PCP) is indicated because infants with HIGM1 are at high risk of developing PCP during the first two years of life. Typical prophylaxis is Bactrim<sup>&#x000ae;</sup> (trimethoprim-sulfamethoxazole) orally or pentamidine by intravenous or inhalation therapy.</p>
            </list-item>
            <list-item>
              <p><bold>Intravenous immune globulin (IVIG).</bold> IVIG replacement should be considered by the time the child is age six months, as individuals with HIGM1 cannot generate antibodies to encapsulated bacteria naturally and are at risk for overwhelming infection from these organisms. IVIG is a highly purified blood derivative (a combination of many specific antimicrobial antibodies) that is typically given every three to four weeks or can be given subcutaneously, usually on a weekly basis.</p>
            </list-item>
            <list-item>
              <p><bold>Additional antibiotic prophylaxis</bold> should be evaluated on a case-by-case basis.</p>
            </list-item>
            <list-item>
              <p><bold>Routine childhood immunizations</bold> (killed vaccines) may be safely administered but do not preclude the need for IVIG replacement.</p>
            </list-item>
          </list>
        </sec>
        <sec id="xlhi.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>In areas where cryptosporidium may be present in the water supply, only purified water should be ingested.</p>
        </sec>
        <sec id="xlhi.Surveillance">
          <title>Surveillance</title>
          <p>Monitor and treat pulmonary complications:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual pulmonary function tests for those older than age seven years</p>
            </list-item>
            <list-item>
              <p>Follow-up of pulmonary infiltrates with a high-resolution chest CT scan, as they may represent lymphoid aggregates</p>
            </list-item>
            <list-item>
              <p>Bronchoscopic evaluations as indicated</p>
            </list-item>
          </list>
          <p>Perform annual endoscopic evaluation.</p>
          <p>At routine visits, monitor for the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Chronic neutropenia</p>
            </list-item>
            <list-item>
              <p>Chronic diarrhea and resulting malnutrition. If present, screen for ova and parasites.</p>
            </list-item>
            <list-item>
              <p>Liver disease with biochemical liver function tests, especially in individuals with documented history of cryptosporidiosis</p>
            </list-item>
            <list-item>
              <p>Lymphomas and GI cancers by history of new symptoms that could be suggestive of malignancy</p>
            </list-item>
            <list-item>
              <p>Autoimmune disorders with history, physical examination, and CBC</p>
            </list-item>
            <list-item>
              <p>Neurologic complications with neurologic examinations and brain MRI, as indicated</p>
            </list-item>
          </list>
        </sec>
        <sec id="xlhi.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to perform molecular genetic testing of <italic toggle="yes">CD40LG</italic> if the pathogenic variant in the family is known so that morbidity and mortality can be reduced by early diagnosis and treatment.</p>
          <p>See <xref ref-type="sec" rid="xlhi.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="xlhi.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="xlhi.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="xlhi.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>X-linked hyper IgM syndrome (HIGM1) is inherited in an X-linked manner.</p>
        </sec>
        <sec id="xlhi.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have HIGM1 nor will he be a carrier of a <italic toggle="yes">CD40LG</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is an obligate carrier. Female carriers of a pathogenic variant in <italic toggle="yes">CD40LG</italic> are asymptomatic and have no immunologic or biochemical markers of the disorder.</p>
            </list-item>
            <list-item>
              <p>If pedigree analysis reveals that the proband is the only affected family member, the mother may be a carrier or the affected male may have a <italic toggle="yes">de novo</italic> pathogenic variant, in which case the mother is not a carrier. <italic toggle="yes">De novo</italic> pathogenic variants occur in approximately one third of affected individuals with no previous family history of the disorder. Therefore, the mother of an affected male who has no family history of HIGM1 has a 2/3 chance of being a carrier of the <italic toggle="yes">CD40LG</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs depends on the carrier status of the mother.</p>
            </list-item>
            <list-item>
              <p>If the mother is a carrier of the <italic toggle="yes">CD40LG</italic> pathogenic variant, the chance of transmitting the pathogenic variant in each pregnancy is 50%. Male sibs who inherit the variant will be affected; female sibs who inherit the variant will be carriers.</p>
            </list-item>
            <list-item>
              <p>Female carriers of <italic toggle="yes">CD40LG</italic> pathogenic variants are asymptomatic and have no immunologic or biochemical markers of the disorder.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism has been demonstrated in this condition. Thus, even if the proband's pathogenic variant has not been identified in DNA extracted from the mother's leukocytes, the sibs remain at increased risk.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Males will pass the pathogenic variant to all of their daughters and none of their sons.</p>
            </list-item>
            <list-item>
              <p>Female carriers of a <italic toggle="yes">CD40LG</italic> pathogenic variant are asymptomatic and have no immunologic or biochemical markers of the disorder.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The proband's maternal aunts or other maternal relatives and their offspring may be at risk of being carriers of a <italic toggle="yes">CD40LG</italic> pathogenic variant (if female) or of being affected with a <italic toggle="yes">CD40LG</italic>-related disorder (if male). The precise risk to the proband's maternal relatives depends on the family relationships.</p>
        </sec>
        <sec id="xlhi.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing of at-risk female relatives is possible if the family-specific pathogenic variant has been identified in an affected male relative.</p>
          <p>If sequence analysis has not been performed on an affected male in the family, direct sequencing of the coding regions of <italic toggle="yes">CD40LG</italic> detects pathogenic variants in approximately 95% of female carriers.</p>
          <p>Note: CD40L expression by flow cytometry is not a reliable carrier test.</p>
        </sec>
        <sec id="xlhi.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="xlhi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="xlhi.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">CD40LG</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for HIGM1 are possible.</p>
        </sec>
      </sec>
      <sec id="xlhi.Resources">
        <title>Resources</title>
      </sec>
      <sec id="xlhi.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">CD40LG</italic> has five coding exons and four introns that span more than 13 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="xlhi" object-id="xlhi.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> To date, no normal variants of <italic toggle="yes">CD40LG</italic> are associated with a change in the amino acid sequence of this protein. Population studies of DNA from 50 normal females from southern Ohio identified several variants in the intronic sequence, but these are highly unlikely to have any pathogenic effect on CD40 ligand [Zhang et al, unpublished].</p>
        <p><bold>Pathogenic variants.</bold> To date, about 170 <italic toggle="yes">CD40LG</italic> pathogenic variants have been published. A database of published <italic toggle="yes">CD40LG</italic> pathogenic variants can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgmd.cf.ac.uk/">www.hgmd.cf.ac.uk</ext-link> (registration required). Pathogenic variants have been described throughout the five exons of the gene but are particularly common in the TNF-homology domain (exon 5):</p>
        <list list-type="bullet">
          <list-item>
            <p>26% of these are missense variants which may affect core packaging, prevent binding to CD40L, or affect trimer formation [<xref ref-type="bibr" rid="xlhi.REF.seyama.1998.2421">Seyama et al 1998</xref>].</p>
          </list-item>
          <list-item>
            <p>20% are nonsense variants that predict premature protein truncation.</p>
          </list-item>
          <list-item>
            <p>The remaining pathogenic variants are small deletions/insertions, splicing variants, and partial- or whole-gene deletions or large insertions.</p>
          </list-item>
        </list>
        <table-wrap id="xlhi.T.selected_cd40lg_pathogenic_varian" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Selected <italic toggle="yes">CD40LG</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-239A&#x0003e;C</td>
                <td headers="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/58331233">NM_000074.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/4557433">NP_000065.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.761C&#x0003e;T</td>
                <td headers="hd_h_xlhi.T.selected_cd40lg_pathogenic_varian_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr254Met</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> CD40 ligand (CD40L) is a small, 261-amino acid transmembrane protein. The protein has three functional domains: an intracytoplasmic domain, a transmembrane domain, and an extracellular domain that shares considerable sequence homology to tumor necrosis factor alpha. CD40 ligand, expressed primarily on CD4+ T cells, binds with CD40 on the surface of B cells to promote immunoglobulin isotype switching. CD40L also plays an important role in T-cell function, particularly in the interaction with monocyte-derived antigen-presenting cells [<xref ref-type="bibr" rid="xlhi.REF.jain.1999.1151">Jain et al 1999</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">CD40LG</italic> lead to changes in the amino acid sequence, abnormal splicing of the protein, premature truncation of the protein, or complete absence of CD40 ligand protein. Persons with pathogenic variants in <italic toggle="yes">CD40LG</italic> are unable to make high-affinity functional antibodies and cytokines, resulting in a high incidence of opportunistic infections.</p>
        <p>Inactivation of <italic toggle="yes">CD40LG</italic> by an AluYb8 element insertion in exon 1 has been reported in a young affected individual [<xref ref-type="bibr" rid="xlhi.REF.apoil.2007.17">Apoil et al 2007</xref>].</p>
        <p>A pathogenic variant at position -123 of the promoter region has been reported to be responsible for the reduction of CD40L protein [<xref ref-type="bibr" rid="xlhi.REF.van_hoeyveld.2007.497">Van Hoeyveld et al 2007</xref>].</p>
      </sec>
      <sec id="xlhi.References">
        <title>References</title>
        <sec id="xlhi.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="xlhi.Literature_Cited.reflist0">
            <ref id="xlhi.REF.aloj.2012.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aloj</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giardino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maio</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espisito</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naddei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cirillo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignata</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Severe combined immunodeficiencies: new and old scenarios.</article-title>
                <source>Int Rev Immunol</source>
                <volume>31</volume>
                <fpage>43</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">22251007</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.antachopoulos.2010.1335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Antachopoulos</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Invasive fungal infections in congenital immunodeficiencies.</article-title>
                <source>Clin Microbiol Infect</source>
                <volume>16</volume>
                <fpage>1335</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">20840542</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.apoil.2007.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Apoil</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhlein</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blancher</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>HIGM syndrome caused by insertion of an AluYb8 element in exon 1 of the CD40LG gene.</article-title>
                <source>Immunogenetics</source>
                <volume>59</volume>
                <fpage>17</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">17146684</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.bonilla.2006.s435">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonilla</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geha</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Update on primary immunodeficiency diseases.</article-title>
                <source>J Allergy Clin Immunol.</source>
                <volume>117</volume>
                <fpage>S435</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">16455342</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.bussone.2009.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bussone</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mouthon</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Autoimmune manifestations in primary immune deficiencies.</article-title>
                <source>Autoimmun Rev</source>
                <volume>8</volume>
                <fpage>332</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19028607</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.davies.2010.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>EG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thrasher</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Update on the hyper immunoglobulin M syndromes.</article-title>
                <source>Br J Haematol</source>
                <volume>149</volume>
                <fpage>167</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">20180797</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.dogu.2011.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dogu</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cipe</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erden</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikinciogullari</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>CD40 ligand deficiency with grade III liver fibrosis, transplanted by a treosulphan-based conditioning regimen.</article-title>
                <source>Exp Clin Transplant</source>
                <volume>9</volume>
                <fpage>349</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">21967264</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.durandy.2005.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Durandy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Revy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hyper-immunoglobulin M syndromes caused by intrinsic B-lymphocyte defects.</article-title>
                <source>Immunol Rev</source>
                <volume>203</volume>
                <fpage>67</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">15661022</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.erdos.2008.455">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erdos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000e1;k&#x000f3;czi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zalatnai</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinbach</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumann</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kropshofer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>T&#x000f3;th</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mar&#x000f3;di</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature.</article-title>
                <source>Clin Immunol</source>
                <volume>129</volume>
                <fpage>455</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">18805740</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF10">
              <mixed-citation publication-type="web">ESID Working Party. Diagnostic criteria for PID: X-linked hyper IgM. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://esid.org/Working-Parties/Clinical/Resources/Diagnostic-criteria-for-PID2#Q16">online</ext-link>. 2006. Accessed 4-27-17.</mixed-citation>
            </ref>
            <ref id="xlhi.REF.ferrari.2001.12614">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giliani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Insalaco</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Ghonaium</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soresina</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loubser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avanzini</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marconi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Badolato</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugazio</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catalan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durandy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tbakhi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>98</volume>
                <fpage>12614</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11675497</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.filipovich.2004">
              <mixed-citation publication-type="book">Filipovich L, Gross T. Immunodeficiency and cancer. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna WG, eds. <italic toggle="yes">Clinical Oncology</italic>. 3 ed. London, UK: Elsevier/Churchill Livingstone; 2004:287-98.</mixed-citation>
            </ref>
            <ref id="xlhi.REF.gallerani.2004.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallerani</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Innocenti</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coronella</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amato</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moretti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabbri</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Cutaneous sarcoid-like granulomas in a patient with X-linked hyper-IgM syndrome.</article-title>
                <source>Pediatr Dermatol</source>
                <volume>21</volume>
                <fpage>39</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">14871324</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.gilmour.2003.256">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gilmour</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walshe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heath</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monaghan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loughlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lester</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norbury</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cale</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM.</article-title>
                <source>Mol Pathol</source>
                <volume>56</volume>
                <fpage>256</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">14514918</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.goldacker.2005.504">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goldacker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnatz</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Tackling the heterogeneity of CVID.</article-title>
                <source>Curr Opin Allergy Clin Immunol</source>
                <volume>5</volume>
                <fpage>504</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16264329</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.hayward.1997.977">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Facchetti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etzioni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnefoy</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosyns</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinberg</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency lwith hyper-IgM.</article-title>
                <source>J Immunol</source>
                <volume>158</volume>
                <fpage>977</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">8993019</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.imai.2003.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catalan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mar&#x000f3;di</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumaki</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagendran</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class switch recombination.</article-title>
                <source>J Clin Invest</source>
                <volume>112</volume>
                <fpage>136</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">12840068</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.jain.1999.1151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atkinson</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipsky</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slater</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strober</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome.</article-title>
                <source>J Clin Invest</source>
                <volume>103</volume>
                <fpage>1151</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10207167</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.jain.2001.223">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ma</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strober</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia.</article-title>
                <source>Nat Immunol</source>
                <volume>2</volume>
                <fpage>223</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11224521</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.jesus.2008.s62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jesus</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duarte</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JB</given-names>
                  </name>
                </person-group>
                <article-title>Autoimmunity in hyper-IgM syndrome.</article-title>
                <source>J Clin Immunol.</source>
                <year>2008</year>
                <volume>28</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S62</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18246414</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.lee.2005.1881">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>WI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torgerson</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schumacher</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome.</article-title>
                <source>Blood</source>
                <volume>105</volume>
                <fpage>1881</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15358621</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.levy.1997.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espanol-Boren</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tovo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordigioni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resnick</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fasth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanders</surname>
                    <given-names>EAM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabone</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plantaz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etzioni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monafo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abinun</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammarstrom</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abrahamsen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klemola</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeVries</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peitsch</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Clinical spectrum of X-linked hyper IgM syndrome.</article-title>
                <source>J Pediatr</source>
                <volume>131</volume>
                <fpage>47</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9255191</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.minegishi.2000.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Minegishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavoie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham-Rundles</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedard</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hebert</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cote</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sedlak</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durandy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.</article-title>
                <source>Clin Immunol</source>
                <volume>97</volume>
                <fpage>203</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">11112359</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.notarangelo.2000.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayward</surname>
                    <given-names>AR</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>X-linked immunodeficiency with hyper-IgM (XHIM).</article-title>
                <source>Clin Exp Immunol</source>
                <volume>120</volume>
                <fpage>399</fpage>
                <lpage>405</lpage>
                <pub-id pub-id-type="pmid">10844515</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.park.2011.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resnick</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham-Rundles</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Perspectives on common variable immune deficiency</article-title>
                <source>Ann N Y Acad Sci</source>
                <volume>1246</volume>
                <fpage>41</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22236429</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.prasad.2005.90">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Velickovic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weston</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Mutational screening of the CD40 ligand (CD40L) gene in patients with X linked hyper-IgM syndrome (XHIM) and determination of carrier status in female relatives.</article-title>
                <source>J Clin Pathol</source>
                <volume>58</volume>
                <fpage>90</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15623492</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.revy.2000.565">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Revy</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geissmann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plebani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catalan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forveille</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufourcq-Labelouse</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gennery</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tezcan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ersoy</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kayserili</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugazio</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brousse</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muramatsu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinoshita</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honjo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durandy</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).</article-title>
                <source>Cell</source>
                <volume>102</volume>
                <fpage>565</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">11007475</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.salzer.2006.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salzer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimbacher</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Monogenetic defects in common variable immunodeficiency: what can we learn about terminal B cell differentiation?</article-title>
                <source>Curr Opin Rheumatol</source>
                <volume>18</volume>
                <fpage>377</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">16763458</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.schuster.2005.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schuster</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Apfelstedt-Sylla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pusch</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zrenner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thirkill</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Autoimmune retinopathy with RPE hypersensitivity and 'negative ERG' in X-linked hyper-IgM syndrome.</article-title>
                <source>Ocul Immunol Inflamm</source>
                <volume>13</volume>
                <fpage>235</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">16019685</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.seyama.1998.2421">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seyama</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonoyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangsaas</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollenbaugh</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pabst</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aruffo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome.</article-title>
                <source>Blood</source>
                <volume>92</volume>
                <fpage>2421</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">9746782</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.sponzilli.2011.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sponzilli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Notarangelo</surname>
                    <given-names>LD</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Severe combined immunodeficiency (SCID): from molecular basis to clinical management.</article-title>
                <source>Acta Biomed</source>
                <volume>82</volume>
                <fpage>5</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">22069950</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.tomizawa.2004.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tomizawa</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kajiwara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minegishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagasawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morio</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonoyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizutani</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience.</article-title>
                <source>Am J Hematol</source>
                <volume>76</volume>
                <fpage>33</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15114594</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.tsuji.2006.469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kajiwara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isoda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomizawa</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maeda</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minegishi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohkawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yata</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kogawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagasawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morio</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonoyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizutani</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years&#x02019; experience of a single team.</article-title>
                <source>Bone Marrow Transplant</source>
                <volume>37</volume>
                <fpage>469</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">16435016</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.van_hoeyveld.2007.497">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Hoeyveld</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>PX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Boeck</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuleihan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bossuyt</surname>
                    <given-names>X</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Hyper-immunoglobulin M syndrome caused by a mutation in the promotor for CD40L.</article-title>
                <source>Immunology</source>
                <volume>120</volume>
                <fpage>497</fpage>
                <lpage>501</lpage>
                <pub-id pub-id-type="pmid">17244160</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.winkelstein.2003.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winkelstein</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marino</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuleihan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholl</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geha</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stiehm</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conley</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>82</volume>
                <fpage>373</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">14663287</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.yong.2011.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yong</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thaventhiran</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimbacher</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>"A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011?</article-title>
                <source>Adv Immunol.</source>
                <volume>111</volume>
                <fpage>47</fpage>
                <lpage>107</lpage>
                <pub-id pub-id-type="pmid">21970952</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="xlhi.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="xlhi.Suggested_Reading.reflist0">
            <ref id="xlhi.REF.ochs.2008.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ochs</surname>
                    <given-names>HD</given-names>
                  </name>
                </person-group>
                <article-title>Patients with abnormal IgM levels:assessment, clinical interpretation and treatment.</article-title>
                <source>Ann Allergy Asthma Immunol.</source>
                <year>2008</year>
                <volume>100</volume>
                <fpage>509</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">18517086</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.shimadzu.1995.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shimadzu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nunoi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terasaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ninomiya</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwata</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanegasaka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuda</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Structural organization of the gene for CD40 ligand: molecular analysis for diagnosis of X-linked hyper-IgM syndrome.</article-title>
                <source>Biochim Biophys Acta</source>
                <volume>1260</volume>
                <fpage>67</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">7999797</pub-id>
              </element-citation>
            </ref>
            <ref id="xlhi.REF.thusberg.2007.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thusberg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vihinen</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The structural basis of hyper IgM deficiency - CD40L mutations.</article-title>
                <source>Protein Eng Des Sel.</source>
                <volume>20</volume>
                <fpage>133</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17307885</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="xlhi.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="xlhi.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>24 January 2013 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>21 June 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 February 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>31 May 2007 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>20 February 2007 (jj) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
